NCT01089101 2026-03-18
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
11 trialsNCT01362803 2026-03-02
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT05309668 2025-12-18
SPRINKLE
AstraZeneca
Phase 1/2 Active not recruiting
NCT03581487 2025-11-05
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT06735820 2025-07-03
MEKMDM2
Children's National Research Institute
Phase 1/2 Not yet recruiting
NCT03705507 2023-05-11
SeluDex
University of Birmingham
Phase 1/2 Terminated
NCT02583542 2020-02-25
TORCMEK
Queen Mary University of London
Phase 1/2 Unknown
NCT01752569 2019-02-20
SCART
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 1/2 Terminated
NCT02025114 2018-07-10
Selumetinib in Combination With Gefitinib in NSCLC Patients
National Taiwan University Hospital
Phase 1/2 Completed
NCT01029418 2015-04-16
AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma
National Cancer Centre, Singapore
Phase 1/2 Terminated